What's new in atopic eczema? An analysis of systematic reviews published in 2018. Part 2: systemic therapies.
Clin Exp Dermatol
; 45(8): 980-985, 2020 Dec.
Article
en En
| MEDLINE
| ID: mdl-32568435
ABSTRACT
This review forms part of an annual update series on atopic eczema (AE), where systematic reviews (SRs) are gathered and appraised to provide a summary of key recent research findings. The focus of this article is systemic therapies used in AE, while a review on prevention and topical therapies is provided in Part 1. In total, 17 SRs on various systemic treatments used in AE were first published or indexed in 2018. There is a lack of evidence to support vitamin D supplementation, montelukast and naltrexone in AE treatment. The adverse effects of systemic corticosteroids are the main barrier to their use, and there is also a lack of data to determine the optimal delivery and duration of treatment with them. Of other immunosuppressants, ciclosporin has the most robust evidence of efficacy. Biologic therapies in AE treatment are being increasingly investigated, and to date, the greatest quantity of data and evidence of efficacy relates to dupilumab. The most commonly reported adverse effects are injection-site reactions and conjunctivitis. Other biologics showing some evidence of efficacy include nemolizumab, lebrikizumab and tralokinumab, although further data are needed. There are currently insufficient data on oral small molecules, including Janus kinase inhibitors, in the treatment of AE. A Cochrane review on probiotics showed no significant benefit, and SRs and meta-analyses on complementary and alternative medicines, including probiotics, in paediatric AE demonstrated significant heterogeneity, thereby limiting their interpretation. This summary of recent SRs provides up-to-date evidence for clinicians on systemic therapies in AE.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Dermatitis Atópica
/
Eccema
Tipo de estudio:
Diagnostic_studies
/
Systematic_reviews
Idioma:
En
Revista:
Clin Exp Dermatol
Año:
2020
Tipo del documento:
Article
País de afiliación:
Reino Unido